We are live on ! Find out more
DRMA icon

Dermata Therapeutics
DRMA

10 hedge funds and large institutions have $297K invested in Dermata Therapeutics in 2025 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 1

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

25% more funds holding

Funds holding: 8 → 10 (+2)

0.16% less ownership

Funds ownership: 0.95% → 0.8% (-0.16%)

47% less capital invested

Capital invested by funds: $561K → $297K (-$264K)

Holders
10
Holders Change
+2
Holders Change %
+25%
% of All Funds
0%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
5
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
XT
XTX Topco
Cayman Islands
+$26.4K
2
UBS Group
UBS Group
Switzerland
+$15.9K
3
TSS
Two Sigma Securities
New York
+$11.3K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$5.35K
5
TRCT
Tower Research Capital (TRC)
New York
+$2.7K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$68.1K
2
Wells Fargo
Wells Fargo
California
-$2.16K

DRMA Hedge Fund Activity: Q2 2025 in Review

10 institutional investors reported a position in Dermata Therapeutics (DRMA) for Q2 2025, worth a combined $297K — down 47% from $561K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new DRMA positions and 1 closed out — a net gain of 2 holders — while 5 added to existing stakes and 1 trimmed.

The largest buyer was XTX Topco, opening a new position worth an estimated $26.4K. The largest seller was Armistice Capital, cutting an estimated $68.1K.

  • 10 institutional investors held Dermata Therapeutics (DRMA) as of Q2 2025, up from 8 in Q1 2025.
  • Funds reported $297K of Dermata Therapeutics stock for Q2 2025, down 47% quarter-over-quarter.
  • 3 funds opened new Dermata Therapeutics positions in Q2 2025 and 1 closed out, a net change of +2 holders.
  • The largest Dermata Therapeutics buyer in Q2 2025 was XTX Topco, an estimated $26.4K added.
  • The largest Dermata Therapeutics seller in Q2 2025 was Armistice Capital, an estimated $68.1K sold.

Based on aggregated 13F filings for Q2 2025.